Kalaris Therapeutics, Inc. (KLRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has a cash flow conversion efficiency ratio of -0.271x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.33 Million) by net assets ($41.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kalaris Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kalaris Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kalaris Therapeutics, Inc. total liabilities for a breakdown of total debt and financial obligations.
Kalaris Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beta Systems Software AG
F:BSS
|
0.005x |
|
Chyang Sheng Dyeing & Finishing Co Ltd
TW:1463
|
0.004x |
|
Taiwan IC Packaging
TWO:3372
|
-0.034x |
|
Right Way Industrial Co Ltd
TW:1506
|
-0.009x |
|
Rama Steel Tubes Limited
NSE:RAMASTEEL
|
-0.061x |
|
Powerwell Holdings Bhd
KLSE:0217
|
0.106x |
|
Star Holdings
NASDAQ:STHO
|
-0.030x |
|
Tillys Inc
NYSE:TLYS
|
0.101x |
Annual Cash Flow Conversion Efficiency for Kalaris Therapeutics, Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kalaris Therapeutics, Inc. from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Kalaris Therapeutics, Inc. (KLRS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $113.31 Million | $-67.70 Million | -0.598x | -290.34% |
| 2023-12-31 | $-45.02 Million | $-14.13 Million | 0.314x | -2.82% |
| 2022-12-31 | $-30.27 Million | $-9.78 Million | 0.323x | +168.44% |
| 2021-12-31 | $225.27 Million | $-106.32 Million | -0.472x | -174.02% |
| 2020-12-31 | $353.06 Million | $-60.81 Million | -0.172x | -3.94% |
| 2019-12-31 | $121.62 Million | $-20.16 Million | -0.166x | -284.07% |
| 2018-12-31 | $21.58 Million | $1.94 Million | 0.090x | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.